APA

Inzucchi S. E., Fitchett D., Jurišić-Eržen D., Woo V., Hantel S., Janista C., Kaspers S., George J. T. & Zinman B. (20210624). Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?. : Diabetes, obesity & metabolism.

Chicago

Inzucchi Silvio E, Fitchett David, Jurišić-Eržen Dubravka, Woo Vincent, Hantel Stefan, Janista Christina, Kaspers Stefan, George Jyothis T and Zinman Bernard. 20210624. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?. : Diabetes, obesity & metabolism.

Harvard

Inzucchi S. E., Fitchett D., Jurišić-Eržen D., Woo V., Hantel S., Janista C., Kaspers S., George J. T. and Zinman B. (20210624). Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?. : Diabetes, obesity & metabolism.

MLA

Inzucchi Silvio E, Fitchett David, Jurišić-Eržen Dubravka, Woo Vincent, Hantel Stefan, Janista Christina, Kaspers Stefan, George Jyothis T and Zinman Bernard. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?. : Diabetes, obesity & metabolism. 20210624.